Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAP3K12 (DLK) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAP3K12 (DLK) Recombinant Protein (Active Kinase Domain / Kinase-Dead Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9 Insect Cell / E. coli Expressed. |
View MAP3K12 Products |
| Gene Delivery | MAP3K12 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cellular target engagement assays. |
View MAP3K12 Products |
| Benchmark Ab | Anti-MAP3K12 Recombinant Antibody Recombinant positive control for western blot, immunofluorescence, and ELISA validation. |
View MAP3K12 Products |
| Validator | MAP3K12 siRNA Set For knockdown verification and target specificity validation in neuronal cell models. |
View MAP3K12 Products |
| Related Target A | MAP3K13 (LZK) High-homology subfamily kinase. Essential for selectivity and off-target counter-screening panels. |
View MAP3K13 Products |
| Related Target B | MAPK8 (JNK1) Downstream kinase in the DLK/JNK pathway. Key readout marker for pathway inhibition validation. |
View MAPK8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against homologous kinases | Highly purified MAP3K12 (DLK) and MAP3K13 (LZK) proteins available for comparative biochemical screening. |
| Kinase-dead assay controls | Sequence-verified kinase-dead mutants (e.g., K185A/R) to exclude background kinase activity. |
| Lack of reliable positive controls | Sequence-defined recombinant benchmark antibodies available. |
| Off-target assay artifacts | Validated siRNA sets included for cellular knock-down specificity controls. |
Live MAP3K12 (DLK) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAP3K12 (DLK) therapeutics is intensifying, with major players shifting focus from broad-spectrum kinase inhibitors to highly selective small molecule inhibitors capable of crossing the blood-brain barrier (BBB). As first-generation therapies reach clinical evaluation for acute and chronic neurodegenerative diseases, the next wave of R&andD is targeting sustained pathway modulation without inducing systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Genentech, Denali Therapeutics | Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease | Selectivity assays (Need MAP3K12 vs MAP3K13 recombinant proteins) |
| Gene Therapy / siRNA | Academic institutions, Biotech startups | Ocular neuropathies, Glaucoma | Target knock-down validation (Need validated MAP3K12 siRNA & Lentivirus) |
| Pathway Modulators | Neuroscience-focused Biopharma | Traumatic Brain Injury (TBI), Neuropathic Pain | Downstream signaling readouts (Need MAPK8/JNK pathway proteins) |